Active replication — ongoing trial, registry, or meta-analysis.
Recent follow-up analyses of CLIMB-121 (exa-cel, sickle cell) are confirming the original effect size in real-world data.
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 0 snapshots
Registry data
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
A Phase 1/2/3 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Severe Sickle Cell Disease
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1009
The CLIMB-121 (exa-cel, sickle cell) trial's stated primary conclusion — CRISPR-Cas9 BCL11A editing (exa-cel) eliminates vaso-occlusive crises in severe sickle cell disease over multi-year follow-up. — replicates in independent cohorts.
0.1163
Recent follow-up analyses of HGB-206 (lovo-cel) are confirming the original effect size in real-world data.
0.1229
Recent follow-up analyses of HOPE-B (Hemgenix / etranacogene) are confirming the original effect size in real-world data.
0.1512
Recent follow-up analyses of ESCAPE are confirming the original effect size in real-world data.
0.1531
Recent follow-up analyses of EMPEROR-Reduced are confirming the original effect size in real-world data.
0.1544
Recent follow-up analyses of EXTEND-IA are confirming the original effect size in real-world data.